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Abstract 
Treatment of Chinese hamster ovary (CHO) cells over-expressing the human insulin receptor (CHO-HIRc) with the insulin mimetic agent, vanadate, 
resulted in a dose- and time-dependent tyrosine phosphorylation of two proteins with apparent molecular sizes of 42 kDa (p42) and 44 kDa (p44). 
However, vanadate was unable to stimulate the tyrosyl phosphorylation of the/%subunit of the insulin receptor. By using myelin basic protein (MBP) 
as the substrate to measure mitogen-activated protein (MAP) kinase activity in whole cell lysates, vanadate-stimulated tyrosyl phosphorylation of 
p42 and p44 was associated with a dose- and time-dependent activation of MAP kinase activity. Furthermore, affinity purification of cell lysates 
on anti-phosphotyrosine agarose column followed by immunoblotting with a specific antibody to MAP kinases demonstrated that vanadate treatment 
increased the tyrosyl phosphorylation of both p41mapk and p42mapk by several folds, as compared to controls, in concert with MAP kinase activation. 
In addition, retardation in gel mobility further confirmed that vanadate treatment increased the phosphorylation of l&lrnapk and p42mapk in 
CHO-HIRc. A similar effect of vanadate on MAP kinase tyrosyl phosphorylation and activation was also observed in CHO cells over-expressing 
a protein tyrosine kinase-deficient insulin receptor (CHO-1018). These results demonstrate that the protein tyrosine kinase activity of the insulin 
receptor may not be required in the signaling pathways leading to the vanadate-mediated tyrosyl phosphorylation and activation of MAP kinases. 
Key words: Mitogen activated protein kinase; Protein tyrosyl phosphorylation; Insulin receptor B-subunit; Protein tyrosine phos- 
phatase; Mutant insulin receptor 
1. Introduction 
The trace element, vanadate, has been shown to mimic 
several of the metabolic and growth promoting effects of 
insulin (reviewed in [1,2]). The most remarkable insuli- 
nomimetic effect of vanadate is its ability to normalise 
blood glucose levels in various animal models of insulin- 
dependent and non-insulin-dependent diabetes mellitus 
[3-71. 
Insulin initiates its biological responses by binding to 
a specific plasma membrane receptor leading to the acti- 
vation, by autophosphorylation, of an intrinsic protein 
tyrosine kinase (PTK) activity of the receptor /?-subunit 
(reviewed in [S]). Insulin receptor autophosphorylation 
and activation of its PTK activity is believed to be a 
major pathway for mediating the pleiotropic effects of 
insulin [8,9]. However, the mechanism by which vana- 
date exerts its insulin-like effect remains controversial. 
Initially, the insulinomimetic effect of vanadate was im- 
plicated in its ability to stimulate insulin receptor PTK 
activity [lo], but recent studies have suggested its action 
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to be distal to the insulin receptor PTK activation [ll- 
131. 
A variety of external stimuli, including insulin, have 
been shown to stimulate a group of closely related pro- 
tein serinelthreonine kinases called mitogen activated 
protein kinases (MAPKs), also termed extracellular sig- 
nal-regulated kinases (ERKs), two of which are known 
as p44mapWERK1 and p42”pWERK2 (reviewed in [14,15]). 
MAPKs/ERKs are activated by phosphorylation on ty- 
rosine and threonine residues by an upstream kinase 
identified as a dual specificity MAP kinase kinase or 
ERK kinase (MEK) [16] and &e believed to play a 
central role in insulin signal transduction [17]. Therefore, 
we undertook the present investigation to examine 
whether, similar to insulin, vanadate can also modulate 
the activation of MAPKs/ERKs and, if an active insulin 
receptor-protein tyrosine kinase is required in this proc- 
ess. In these studies we have used Chinese hamster ovary 
(CHO) cells over-expressing either a wild-type (CHO- 
HIRc) or a protein tyrosine kinase-deficient insulin re- 
ceptor (CHO-1018). We demonstrate that vanadate 
mimics insulin in stimulating the tyrosyl phosphoryla- 
tion and activation of two isoforms of MAPK/ERKs, 
p44mapk and p42mapk. However, the vanadate-mediated 
effects were independent of insulin receptor autophos- 
phorylation. 
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2. Materials and methods 
2.1. Materials 
Parental CHO cells, CHO cells over-expressing a mutant human 
insulin receptor in which Lys “‘* has been replaced by alanine causing 
a complete loss of the PTK activity of insulin receptor (CHO-1018), and 
CHO cells over-expressing a normal human insulin receptor (CHO- 
HIRc), were a kind gift from Dr. Morris F. White (Joslin Diabetes 
Centre, Boston, MA, USA). Insulin receptor antibody was generously 
provided by Dr. Barry I. Posner (Royal Victoria Hospital, McGill 
University, Mont&al, Qu&, Canada). Insulin was from Eli Lilly Co. 
(Indianapolis, IN, USA). Myelin basic protein (MBP) and sodium 
orthovanadate were purchased from Sigma Chemical Co. (St. Louis, 
MO, USA). Anti-phosphotyrosine antibody, anti-MAP kinase anti- 
body (raised against a peptide based upon residues 333-367 of the 
C-terminus of the rat 43 kDa ERKl) that detects several isoforms of 
MAP kinases, including ~44~~~~ and p42 mapk and anti-phosphotyrosine 
affinity column were from Upstate Biotecdnology (Lake Placid, NY, 
USA). Goat anti-mouse or anti-rabbit IgG conjugated to alkaline phos- 
phatase were purchased from Bio-Rad (Mississauga, Ont., Canada). 
2.2. Cell culture 
CHO cells were maintained on HAM’s F-12 medium containing 10% 
foetal bovine serum. Cells were grown to confluence in 100 mm plates 
and incubated in serum-free F-12 medium for 18 h prior to the exper- 
iment. 
2.3. DetectIon of phosphotyrosine-containing proteins 
Tyrosine phosphorylation of cellular proteins stimulated in the ab- 
sence or presence of insulin or vanadate was assessed by immunoblot- 
ting using anti-phosphotyrosine antibodies. Cells were stimulated with 
various concentrations of insulin and vanadate for the indicated time 
periods. The cells were lysed on ice in 400 ~1 of buffer A (25 mM 
Tris-HCl, pH 7.5, 25 mM NaCI, 1 mM Na-vanadate, 10 mM Na- 
fluoride, 10 mM Na-pyrophosphate, 20 nM okadaic acid, 0.5 mM 
EGTA, 1 mM phenylmethylsulphonyl fluoride, 10 &ml aprotinin, 1% 
Triton X-100, and 0.1% SDS). The lysates were clarified by centrifuga- 
tlon for 10 min at 10,000 x g and the supematant boiled in Laemmli’s 
sample buffer [18]. The samples were then electrophoresed on 10% 
SDS-polyacrylamide gels [19], transferred to polyvinilidene difluoride 
(PVDF) membranes, blotted with anti-phosphotyrosine antibody 
(1:lOO) and detected using goat anti-mouse IgG conjugated to alkaline 
phosphatase (1:3,000). 
2.4. Immunoafjnity p&cation ofphosphotyrosyl protems and MAP 
kinase immunoblotting 
The cell lysates were affinity-purified on anti-phosphotyrosine-aga- 
rose column and immunoblotted using a MAP kinase antibody. For 
affinity purification of phosphotyrosyl proteins, briefly, the clarified 
cell lysates from control or stimulated cells were incubated for 30 min 
at 4°C with anti-phosphotyrosine agarose beads equilibrated in buffer 
B (20 mM Tris-HCI, pH 7.4, 1% Nonidet P-40, 10 mM EDTA, 0.2 mM 
Na-vanadate, 0.01% Na-azide, and 100 mM NaCI). The beads were 
washed 3 times with buffer B, and phosphotyrosine-containing proteins 
were eluted with 1 mM phosphotyrosine in buffer B. The eluates were 
boiled in 3x Laemmli’s sample buffer, electrophoresed on 10% SDS- 
polyacrylamide gels, transferred to PVDF membranes, blotted with 
anti-MAP kinase antibody (1500) and detected using goat anti-rabbit 
IgG conjugated to alkaline phosphatase. In the gel-shift experiments, 
MAP kinase immunoblotting was performed on whole cell lysates from 
control and stimulated CHO-HIRc cells. 
2.6. Insulin receptor immunopreclpitation 
2 5. MAP kinase assay 
MAP kinase activity was determined using MBP as an exogenous 
substrate. To 5 ~1 of cell lysate (approximately 3-4 fig protein), 40 ~1 
of kinase buffer (25 mM Tris-HCl, pH 7.4, 10 mM MgCl,, 2 mM 
M&l,. 1 mM dithiothreitol, 40 fiM ATP, 1 PM staurosporin, 15 fig 
MBP,i.5 mM EGTA, and 0.2pCi [y’*P]ATP)was added. After 12 min. 
at 3O”C, the reaction was stopped by adding 70 ~1 of 2x sample buffer. 
Samples were electrophoresed on 12% SDS-polyacrylamide mini gels, 
transferred on PVDF membranes and autoradiographed. In some ex- 
periments, the reaction was stopped by spotting 20 pl of the reaction 
mixture onto P-81 filter papers (2 x 2 cm), washed 4 times in 0.6% 
phosphoric acid and radioactivity counted. 
CHO-HIRc cells were prellabelled with [“Plorthophosphate 
(0.2 mCi/ml) for 3 h. The cells were then stimulated for 5 min in the 
gbsence or presence of 100 nM insulin or 100 PM vanadate. The cells 
were washed 3 times with ice-cold PBS, frozen in liquid N, and lysed 
in buffer A. The lysate was centrifuged for 10 min at 10,000 x g and 
pre-cleared with protein A-Sepharose for 30 min. The pre-cleared ly- 
sate was incubated with the insulin receptor antibody for 4 h at 4°C and 
the immunoprecipitate was collected with protein A-Sepharose. 
washed 3 times with 50 mM HEPES buffer, pH 7.5, containing 0.1% 
Triton X-100 and 0.1% SDS, and 2 times with the above buffer without 
SDS. The immunoprecipitate was solubilized by boiling in sample 
buffer for 5 min. The solubilized fraction was electrophoresed on 10 
SDS-polyacrylamide gels and transferred on PVDF membranes. PVDF 
membranes were treated with 1 M KOH for 2 h at 55°C to remove the 
phosphoserinelthreonine [20] and autoradiographed (191. 
3. Results 
3.1. Effect of vanadate on protein tyrosine phosphoryl- 
ation and MAP kinase activation 
Treatment of CHO-HIRc cells with vanadate resulted 
in the tyrosyl phosphorylation of two major proteins 
corresponding to the molecular sizes of 44 kDa and 42 
kDa (p44/p42) (Fig. 1A). The stimulation was concentra- 
tion-dependent and was maximal at 0.1 mM (Fig. 1A). 
As expected, insulin stimulation of cells increased the 
tyrosyl phosphorylation of two more proteins of molecu- 
lar sizes of 95 kDa and 185 kDa in addition to p44 and 
p42 (Fig. 1B). These two additional proteins with molec- 
ular sizes of 95 kDa and 185 kDa represent he insulin 
receptor p-subunit [21] and insulin receptor substrate-l 
(IRS-l) [22], respectively. In vanadate-treated cells, how- 
ever, there was no detectable phosphorylation of either 
the insulin receptor B-subunit or the IRS- 1 even at 1 mM 
vanadate (Fig. lA,B). Insulin-stimulated p44 and p42 
phosphotyrosyl proteins have previously been identified 
as p44mapk and p42mapk, respectively [ 141. Since the molec- 
ular sizes of two MAP kinase isoforms, the tyrosyl phos- 
phorylation and activation of which is stimulated by 
vanadate, are also 44 kDa and 42 kDa, it was of interest 
to investigate whether vanadate-mediated tyrosyl phos- 
phorylation of these proteins is associated with an activa- 
tion of the MAP kinase activity. As shown in Fig. lC, 
treatment of CHO-HIRC cells with vanadate stimulated 
the MAP kinase activity, in a concentration dependent- 
manner, as judged by the increased phosphorylation of 
MBP. A significant MAP kinase activation was detecta- 
ble at vanadate concentrations as low as 10 FM, which 
correlated with the degree of tyrosyl phosphorylation of 
p44 and p42 (Fig. 1A). 
We next investigated the time-course of vanadate-me- 
diated tyrosyl phosphorylation and MAP kinase activa- 
tion in whole cell lysates. Exposure of CHO-HIRc cells 
with 100 ,uM vanadate resulted in a rapid and sustained 
tyrosyl phosphorylation of p44 and p42 (Fig. 2A). The 
increased phosphorylation was detectable as early as 1 
min, reached a maximum at 2 min and remained un- 
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Fig. 1. Effect of vanadate and insulin on protein tyrosine phosphoryla- 
tion and MAP kinase activation. (A) CHO-HIRc cells were treated with 
the indicated concentrations of vanadate for 5 min. Cell lysates were 
C 
[ Vanadate ] pm 
prepared and immunoblotted with anti-phosphotyrosine antibodies as 
described in section 2. (B) CHO-HIRc cells were treated in the absence 
IC) or presence of either 10 nM insulin (I) or 100 ,uM vanadate (V) for 
0 1 10 100 1000 
5 min and the cell lysates were immunoblotted with anti-phosphoty- 
rosineb antibody as described above. (C) Autoradiograph showing 
MAP kinase activation in whole cell lysates. Cells were treated with the 
Indicated concentrations of vanadate for 5 min and MAP kinase was 
assayed using myelin basic protein (MBP) as the substrate as described 
MBP_+ 
m section 2. Immunoblots and autoradiographs are representative of 
at least 5 similar experiments. The numbers in the left indicate the 
position of molecular weight standards. 
changed thereafter until 14 min (Fig. 2A). In contrast, 
however, the MAP kinase activation was maximal be- 
tween 2 and 5 min of vanadate stimulation and declined 
at 14 min (Fig. 2B). It is interesting to note that despite 
the absence of a significant change in the degree of ty- 
rosy1 phosphorylation of ~44 and p42 at 15 min (Fig. 
2A), the extent of MAP kinase activation had signifi- 
cantly declined (Fig. 2B), probably due to 
dephosphorylation of threonine residues by protein 
serinelthreonine phosphatases. 
3.2. Ident$cation of p44lp42 as MAP kinases 
In order to ascertain whether ~44 and ~42 are indeed 
MAP kinases, the phosphotyrosyl proteins in lysates 
from insulin- and vanadate-treated cells were im- 
munopurified on an anti-phosphotyrosine affinity col- 
umn and the eluted phosphotyrosyl proteins were ana- 
lyzed using a MAP kinase antibody. As shown in Fig. 
3A, the antibody recognized two protein bands with ap- 
parent molecular sizes of 44 and 42 kDa corresponding 
to the two isozymic forms of ~44”‘~~~ and p42mapk, respec- 
tively [14]. These bands were detectable only in insulin- 
or vanadate-stimulated cells and not in unstimulated 
control cells (Fig. 3A), demonstrating that vanadate, 
similar to insulin, could increase the tyrosyl phosphoryl- 
ation of ~44”‘~p~ and p42mapk. To examine whether there 
was a correlation between tyrosyl phosphorylation of 
p44mapk and p42mapk and MAP kinase activation, the im- 
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Fig. 2. Time-course of vanadate-stimulated protein tyrosine phospho- 
rylation and MAP kinase activation in CHO-HIRc cells. (A) The cells 
were treated with 100 ,uM vanadate at the indicated time periods, and 
the cell lysates were prepared and immunoblotted with anti-phosphoty- 
rosine antibody as described in section 2. (B) Autoradiograph showing 
MAP kinase activation. Cells were treated with 100 PM vanadate for 
indicated time periods and MAP kinase was assayed in whole cell 
lysates as m Fig. 1. Immunoblots and autoradiographs are representa- 
tive of at least 5 similar experiments. 
munoaffinity-purified phosphotyrosyl proteins obtained 
above were assayed for MAP kinase activity. As judged 
by the increased phosphorylation of MBP, insulin, as 
well as vanadate, stimulated the MAP kinase activity by 
3 to 5-fold (Fig. 3B) as compared to controls. Since MAP 
kinase activation has been associated with a shift in its 
mobility on SDS-PAGE, we examined whether vana- 
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date-mediated activation of MAP kinases resulted in a 
similar gel mobility shift. Indeed, as demonstrated by 
immunoblotting with MAP kinase antibodies, the lysates 
from vanadate- and insulin-treated cells exhibited a char- 
acteristic retardation in the mobility of p44”“P” and 
~42”“pk, as compared to unstimulated control cells (Fig. 
3C). 
3.3. Effect oj’vanadate on insulin receptor 
phosphorylation 
Since the immunoblotting experiments using anti- 
phosphotyrosine antibodies failed to detect yrosyl phos- 
phorylation of insulin receptor /?-subunit in vanadate- 
stimulated HIRc cells, we further confirmed this effect 
by prelabeling the cells with [32P]orthophosphate fol- 
lowed by stimulation with either vanadate or insulin. 
Immunoprecipitation of 3’P-labeled insulin receptor 
from these cells with a specific antibody to the p-subunit 
of the insulin receptor revealed that, although insulin 
treatment increased the tyrosyl phosphorylation of /?- 
subunit of insulin receptor, a similar increase in tyrosyl 
phosphorylation was not detected in cell stimulated with 
0.1 mM vanadate (Fig. 4). 
To further verify the role of insulin receptor PTK in 
vanadate-mediated tyrosyl phosphorylation and activa- 
tion of MAP kinases, CHO cells over-expressing a PTK- 
deficient insulin receptor (CHO-1018) were used. As 
shown in Fig. 5A, treatment of either parental CHO cells 
(CHO-NEO) or CHO-1018 with 100 ,uM vanadate for 5 
min resulted in tyrosyl phosphorylation of two major 
proteins with molecular sizes of 44 and 42 kDa (p44/ 
~42). Under these conditions, however, tyrosyl phospho- 
rylation of insulin receptor P-subunit was not detected. 
These results are similar to those observed with CHO 
cells expressing wild-type insulin receptors (Fig 1 A, 1 B). 
Furthermore, vanadate-stimulated tyrosyl phosphoryla- 
tion of ~4.41~42 correlated with a corresponding activa- 
tion of MAP kinase in CHO-NE0 as well as in CHO- 
1018 cells. In both cell types vanadate stimulated the 
MAP kinase activity by about 4-fold, as compared to 
untreated control cells (Fig. 5B). In addition, analysis of 
cell lysates purified on an anti-phosphotyrosyl affinity 
column followed by immunoblotting with a MAP kinase 
antibody revealed that vanadate treatment of CHO- 1018 
and CHO-NE0 cells increased the phosphotyrosyl con- 
tent of the both ~42~~~~ as well as ~44”~~~ in aconcentra- 
tion-dependent manner (Fig. 5C). 
4. Discussion 
The results presented here demonstrate that the insu- 
linomimetic agent, vanadate, stimulates the tyrosyl phos- 
phorylation and activation of ~44”‘~~~ and ~42~~~~ in 
CHO cells over-expressing either a normal or PTK-defi- 
cient human insulin receptor. However, unlike insulin, 
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Fig. 3. Effect of insulin and vanadate on tyrosyl phosphorylation of 
MAP kinases. CHO-HIRc cells were incubated in the absence (C) or 
presence of either 10 nM insulin (I) or 100 PM vanadate (V) for 5 min 
and ceil lysates were prepared. (A,B) Cell lysates were subjected to 
immunoaffinity purification on an anti-phosphotyrosine affinity col- 
umn and the phosphotyrosine eluates were subjected to (A) im- 
munoblotting using anti-MAP kinase antibody, and (B) MAP kinase 
assay using MBP as the substrate as described in section 2. (C) Gel 
mobility shift of p44”‘“r’ and p42”““. Lysates from cells treated with 
C, I or V were immunoblotted with MAP kinase antibody. These results 
are representative of 5 similar experiments. 
the vanadate-mediated activation of p44mapk and p42mapk 
was not associated with the tyrosyl phosphorylation of 
insulin receptor /?-subunit, even in CHO-HIRc. The lack 
of any effect of vanadate on insulin receptor tyrosyl 
phosphorylation is at variance with the results of Ta- 
mura et al. [lo], who observed an increased tyrosyl phos- 
phorylation of insulin receptor by vanadate. On the 
other hand, it is in agreement with several other studies 
[l l-13,23]. In mouse diaphragm, in vivo administration 
of vanadate activated glycogen synthesis but failed to 
alter either the phosphorylation status or protein tyro- 
sine kinase activity of the insulin receptor p-subunit [l 11. 
Vanadate-mediated activation of MAP kinases was sim- 
ilar in all types of CHO cells used in this study and 
occurred even in the absence of the tyrosyl phosphoryla- 
tion of insulin receptor B-subunit. It is interesting to note 
that CHO-1018 cells have been shown to be unrespon- 
sive in mediating the various metabolic or growth pro- 
moting effects of insulin [24,25]. It was also demon- 
strated recently that insulin fails to activate MAP kinases 
in CHO-1018 cells [26,27]. 
MAP kinase activation was also observed in CHO 
cells over-expressing PTK-deficient epidermal growth 
factor (EGF) receptors [28,29], and the authors indicated 
that MAP kinase was activated in response to a signal 
other than the EGF receptor, PTK. Our observations 
support this notion since MAP kinase activation oc- 
c I v 
IR --_) 
Fig. 4. Effect of vanadate on insulin receptor autophosphorylation. 
[32P]Orthophosphate-pre-labeled CHO-HIRc cells were treated without 
(C) or with 100 nM insulin (I) or 100 PM vanadate (V) for 5 min. The 
cells were lysed and insulin receptor was immunoprecipitated with 
insulin receptor antibody as described in section 2. The immunoprecip- 
itates were subjected to SDS-PAGE followed by KOH treatment and 
autoradiography, as described in section 2. The results are representa- 
tive of at least 5 similar experiments. 
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Fig. 5. Effect of vanadate on protein tyrosme phosphorylation and MAP kinase activation in parental (NEO) and insulin receptor protein tyrosine 
kinase-deficient CHO cells (CHO-1018). CHO-NE0 and CHO-1018 cells were treated with 100,~M vanadate for 5 min. (A) Cell lysates were prepared 
and immunoblotted with anti-phosphotyrosine antibodies as described in section 2. (B) Cell lysates were subjected to MAP kinase assay using MBP 
as the substrate as described in section 2. Results represent he mean values f S.E.M. of 4 (control) and 6 (vanadate-stimulated) independent 
experiments. (C) Cell lysates from A were subjected to immunoaftinity purification on an anti-phosphotyrosine antibody affinity column and the 
phosphotyrosine luates were subjected to immunoblotting with MAP kinase antibody. 
curred in the absence of receptor autophosphorylation. 
Our results on vanadate-mediated tyrosyl phosphoryla- 
tion and activation of MAP kinases are intriguing and 
demonstrate for the first time vanadate per se could stim- 
ulate the tyrosyl phosphorylation of proteins. Earlier 
studies using several cell types have failed to detect any 
alteration in protein tyrosine phosphorylation with va- 
nadate alone [30-341. However, the reason for this dis- 
crepancy is not clear and may be due to the differences 
in the experimental conditions used. Recently, Scimeca 
et al. [35] demonstrated that vanadate was able to stimu- 
late a kemptide kinase activity recovered in anti- 
phosphotyrosyl immunoprecipitates from NIH 3T3 cells 
over-expressing human insulin receptor. However, no 
attempt was made either to identify and characterise this 
kinase or to determine whether this stimulation was asso- 
ciated with tyrosyl phosphorylation of insulin receptor 
B-subunit [35]. 
The mechanism by which vanadate stimulates the ty- 
rosy1 phosphorylation and activation of MAP kinases is 
not known. Since vanadate is a potent inhibitor of pro- 
tein tyrosine phosphatases (PTPases) [36], it is possible 
that, by preventing the dephosphorylation of tyrosyl 
phosphorylated insulin receptor B-subunit, it may cause 
an activation of insulin receptor PTK and mimic insulin 
in stimulating MAP kinases. However, the results pre- 
sented here, as well as those of others [l l-131, showing 
the lack of any effect of vanadate on the tyrosine phos- 
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phorylation of insulin receptor /?-subunit, would argue 
against his possibility. It may still be possible that vana- 
date, by inhibiting a MAP kinase-specific PTPase(s), in- 
creases the tyrosyl phosphorylation as well as activation 
status of the MAP kinases. Recently, a MAP kinase- 
specific protein phosphatase which is inhibited by vana- 
date in vitro has been described [37]. However, it remains 
to be tested if this phosphatase is expressed in CHO cells 
and if the inhibition occurs in vivo. 
Vanadate was shown to inhibit the Ca2’/Mg2’-ATPase 
and CA’+ transport system with an IDSo of 30 PM and 
144 PM, respectively [38]. Moreover, it was demon- 
strated recently that mobilisation of intracellular sources 
of Ca” is sufficient to activate MAP kinases [39]. There- 
fore, another plausible explanation for our observations 
could be that by virtue of its ability to inhibit the Ca”/ 
Mg”-ATPase pump vanadate might increase intracellu- 
lar Ca” and thereby stimulate the MAP kinases activ- 
ity. 
Furthermore, upstream regulators of MAP kinases 
[15], such as MAP kinase kinase (MEK) or MEK kinase, 
may also be modulated by vanadate. Alternatively, it is 
also possible that vanadate diverges from the insulin 
signaling pathway and activates an unidentified kinase 
which triggers MAP kinase activation. One such candi- 
date may be a novel cytosolic PTK which is stimulated 
solely be vanadate in rat adipocytes [40]. 
In summary, these results demonstrate that vanadate 
phosphorylates and stimulates the two isoforms of MAP 
kinases in the absence of insulin receptor B-subunit ty- 
rosy1 phosphorylation, and suggest that the PTK activity 
of the insulin receptor may not be required in signalling 
pathways leading to activation of MAP kinases by vana- 
date. 
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